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ABSTRACT
Objective: To compare weight change over time in patients with Parkinson disease (PD), those
with atypical parkinsonism, and matched controls; to identify baseline factors that influence
weight loss in parkinsonism; and to examine whether it predicts poor outcome.
Methods:We analyzed data from the Parkinsonism Incidence in North-East Scotland (PINE) study,
an incident, population-based prospective cohort of parkinsonian patients and age- and sex-
matched controls with annual follow-up. Mixed-model analysis described weight change in pa-
tients with PD, those with atypical parkinsonism, and controls. Baseline determinants of sus-
tained clinically significant weight loss (.5% loss from baseline) and associations between
early sustained weight loss and death, dementia, and dependency in parkinsonism were studied
with Cox regression.
Results: A total of 515 participants (240 controls, 187 with PD, 88 with atypical parkinsonism)
were followed up for a median of 5 years. At diagnosis, atypical parkinsonian patients had lower
body weights than patients with PD, who were lighter than controls. Patients with PD lost weight
more rapidly than controls, and weight loss was most rapid in atypical parkinsonism. After multi-
variable adjustment for potential confounders, only age was independently associated with sus-
tained clinically significant weight loss (hazard ratio [HR] for 10-year age increase 1.83, 95%
confidence interval [CI] 1.44–2.32). Weight loss occurring within 1 year of diagnosis was inde-
pendently associated with increased risk of dependency (HR 2.11, 95%CI 1.00–4.42), dementia
(HR 3.23, 95% CI 1.40–7.44), and death (HR 2.23, 95% CI 1.46–3.41).
Conclusion: Weight loss occurs in early parkinsonism and is greater in atypical parkinsonism than
in PD. Early weight loss in parkinsonism has prognostic significance, and targeted dietary inter-
ventions to prevent it may improve long-term outcomes. Neurology® 2017;89:2254–2261
GLOSSARY
CI 5 confidence interval; DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders, 4th edition; HR 5 hazard ratio;
PD 5 Parkinson disease; PINE 5 Parkinsonism Incidence in North-East Scotland.
Previous studies have shown that weight loss is common in Parkinson disease (PD),1,2 is not
explained solely by reduced nutritional intake or increased energy expenditure,3 and may be
associated with worse outcomes.4–9
However, these previous studies have generally been based on small, highly selected cohorts
(frequently relatively young-onset patients) with limited or no follow-up.1,3–5,8 Only 2 studies
have compared the degree of weight loss and its early risk factors in PD,5,10 but none has
compared PD with other atypical parkinsonian syndromes, compared patients with PD with
controls over long-term follow-up from diagnosis in an unselected incident cohort of patients, or
assessed the effect of early weight loss on long-term outcomes. Hence, uncertainty remains in the
degree, causes, and relevance of weight loss in PD and other parkinsonian syndromes.
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We aimed to compare weight change over
time in parkinsonian patients with age- and
sex-matched controls, to determine which fac-
tors measured at diagnosis are associated with
developing sustained clinically significant
weight loss in parkinsonism, and to evaluate
the effect of early significant weight loss in par-
kinsonism on clinical outcomes.
METHODS Study design. The Parkinsonism Incidence in
North-East Scotland (PINE) study is a population-based incident
cohort of parkinsonism with annual prospective lifelong follow-
up.11,12 The study design and recruitment methods were previously
described.11,12 In brief, multiple ascertainment strategies were used
to identify all new diagnoses of degenerative or vascular parkin-
sonism occurring in a population ofz300,000 during 2 incidence
periods, 2002 to 2004 and 2006 to 2009. Patients were invited to
consent to lifelong follow-up. Age- and sex-matched controls were
recruited from the same general practice as each recruited patient.
Patients and controls had annual assessment including clinical
history and examination, review of medical case notes, and various
assessment scales. Body weight was measured annually with regu-
larly calibrated hospital scales.
Patients’ diagnoses were reviewed annually by a neurologist
with a special interest in movement disorders or by supervised
specialist trainees in neurology or geriatric medicine. Clinical
diagnoses were guided by appropriate research criteria, e.g., the
Parkinson’s UK Brain Bank criteria.11,13 Controls and parkinso-
nian patients with at least 2 weight measurements throughout
clinical follow-up were included in these analyses. The parkinso-
nian group was analyzed separately as those with PD and those
with atypical parkinsonism.
Standard protocol approvals, registrations, and patient
consents. Ethics approval was obtained from the Grampian
Research Ethics Committee and the Multi-Centre Research
Ethics Committee for Scotland. All participants gave written
informed consent.
Weight data. The PINE study database was screened for miss-
ing annual weight data. When those data were missing, available
sources (medical and nursing notes, GP summaries) were exam-
ined for weights measured within 6 months of the date of the
visit.
In this study, clinically significant weight loss was defined as
loss of .5% of baseline body weight as previously described.14
Follow-up weight measurements were screened to identify those
participants with sustained clinically significant weight loss (i.e.,
weight loss of .5% of the baseline weight, with all subsequent
weight measurements being .5% less than baseline weight).
Outcome data. We selected 3 clinically relevant outcomes of
interest: dependency (need for help with basic activities of daily
living), dementia, and death. Dependency was defined as
a Schwab and England score ,80.15 Dementia was diagnosed
with a DSM-IV definition based on clinical interview supple-
mented by cognitive testing with the Mini-Mental State Exami-
nation and Mini-Mental Parkinson’s.16 All participants were
flagged with the NHS central register for regular notifications of
deaths.
Statistical analysis. Description of weight change in patients
with PD, those with atypical parkinsonism, and controls. We
used a repeated-measures linear mixed model to describe weight
change over time. Annual weight measurements were set as the
dependent variable. Age, diagnostic group (PD, atypical parkin-
sonism, controls), and years of follow-up were entered as main
fixed-effect factors, and interactions between each fixed effect and
weight measurements were also included. A first-order autore-
gressive covariance structure was assumed. Yearly estimates of
mean weight change were calculated from marginal means from
the model, and the significance of the interaction between diag-
nosis and years of follow-up was used to determine whether the
change in weight over time was different between diagnostic
groups. To determine whether weight change over time was
different between PD and atypical parkinsonism, we repeated the
model excluding controls and tested the significance of the
interaction between PD/atypical parkinsonism diagnosis and year
of follow-up. Similarly, the model was repeated for controls and
patients with PD only.
Determinants of weight loss in parkinsonism. Baseline de-
terminants (factors measured at the first [diagnostic] visit) of sus-
tained significant weight loss in parkinsonian patients were
investigated with multivariable Cox regression. The following
variables were considered for entry in the model: age; sex; PD
vs atypical parkinsonism; baseline Charlson comorbidity score17;
presence of hallucinations; self-reported problems with swallow-
ing; low mood and memory; dependency (Schwab and England
score ,80); dementia; Barthel Index; Mini-Mental State Exam-
ination; Parkinson’s Disease Questionnaire 8; Unified Parkin-
son’s Disease Rating Scale parts I, II, and III subscores; and
Hoehn-Yahr score. Cases without clinically significant weight
loss were censored at the date of the last available weight mea-
surement. Univariable analyses of the baseline covariates were
examined. Variables with statistical significance (p, 0.05) in the
univariable analysis were included in a backward stepwise selec-
tion process, with p . 0.1 being the criterion for removal from
the model to reduce the likelihood of chance findings in the
models. Variables with .10% of missing data and variables that
showed important collinearity with other variables were excluded.
To avoid overfitting in the final models, we ensured that the ratio
of events to variable was ,10.18
Prognosis of clinically significant weight loss in
parkinsonism. Three separate multivariable Cox regression
models were constructed to assess the associations between
sustained clinically significant weight loss within the first year
of diagnosis and dependency, dementia, and death. Patients who
developed an outcome of interest within the first year of diagnosis
were excluded from the analyses predicting that outcome. Losses
to follow-up were censored at the date of last follow-up, and
data were extracted for analysis on December 31, 2014.
The same variables and selection strategy for models assessing
outcomes as described above were used for the model of time to
sustained significant weight loss.
For each Cox model, the proportional hazards assumption
was checked by visual inspection of the Kaplan-Meier survival
plots. Complete-case analysis was performed for each Cox model;
i.e., patients with missing data were removed from each model.
Sensitivity analysis. We also performed a post hoc sensitivity
analysis to examine whether excluding patients with vascular par-
kinsonism (which is not strictly neurodegenerative) from the
atypical parkinsonism group altered our results.
We used Statistical Package for Social Sciences version 21.0
(SPSS Inc, Chicago, IL) and Stata version 12.1 (StataCorp,
College Station, TX) to perform the analyses.
RESULTS Of 355 patients with parkinsonism and
266 controls in the PINE study, 187 with PD, 88
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with atypical parkinsonism, and 240 controls were
included. Reasons for exclusions are given in figure
1. The atypical parkinsonian group included those
with corticobasal degeneration (n 5 2), dementia
with associated parkinsonism (n5 4), dementia with
Lewy bodies (n5 26), multiple system atrophy (n5
14), progressive supranuclear palsy (n 5 18), and
vascular parkinsonism (n5 24). Patients and controls
were followed up for up to 12 years (mean duration
until death, loss to follow-up, or last follow-up 6.9
years in controls, 6.3 years in patients with PD, and
4.2 years in those with atypical parkinsonism). Only
1 patient and 1 control were lost to follow-up for
reasons other than death.
Description of weight change in patients with PD, those
with atypical parkinsonism, and controls. Baseline char-
acteristics and comparisons between individuals with
and without sustained clinically significant weight
loss are presented in table 1. On average, atypical
parkinsonian patients were older than those with
PD, and there were more men. At diagnosis, patients
with PD and atypical parkinsonian patients were sig-
nificantly lighter than controls by 5.6 and 7.1 kg,
respectively, after adjustment for age and sex (p ,
0.001). After diagnosis, weight reduced in all study
groups (figure 2). Mean (SD) for the decrease in
weight from baseline until the last follow-up visit
was 3.2 (6.9), 4.1 (8.6), and 5.0 (7.6) kg in controls,
patients with PD, and those with atypical parkin-
sonism, respectively. These data were not obviously
skewed (median decreases 3, 4, and 5 kg). Patients (all
with parkinsonism) lost weight more quickly than
controls (p 5 0.001 for the interaction between
patient/control status and year). Patients with PD lost
weight more quickly than controls (p 5 0.02 for the
interaction between controls/those with PD and
year). Patients with atypical parkinsonism lost weight
more quickly than those with PD (p 5 0.001 for the
interaction between PD/atypical parkinsonism
and year). Sustained clinically significant weight loss
within the first year of diagnosis was more common
Figure 1 Study flowchart
Flowchart of Parkinsonism Incidence in North-East Scotland (PINE) study participants.
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Table 1 Baseline characteristics of controls and parkinsonian patients with no weight loss, sustained weight loss within the first year of diagnosis, and sustained weight loss at any time throughout
follow-up
Baseline variable
Controls (n 5 240) IPD (n 5 187) Atypical parkinsonian syndromes (n 5 88)
No WL
WL in first
year
WL at any
time All controls No WL
WL in first
year WL at any time All IPD No WL WL in first year WL at any time All APS
No. (%) 156 (65) 18 (8) 84 (35) 240 114 (61) 15 (8) 73 (39) 187 48 (55) 19 (22) 40 (45) 88
Age, ya 73.6 (69.3) 74.8 (611.0) 76.7 (68.2) 74.7 (69.1) 69.7 (611.3) 76.5 (68.0) 75.1 (67.8) 71.8 (610.4) 77.0 (66.8) 79.5 (68.0) 78.8 (67.8) 77.8 (67.3)
Female, n (%) 55 (35) 6 (33) 37 (44) 92 (38) 46 (40) 6 (40) 32 (44) 78 (42) 17 (35) 10 (53) 16 (40) 33 (38)
Weight,a kg 77.6
(613.0)
84.3 (618.5) 76.6 (616.4) 77.3
(614.3)
73 (613.9) 69.9 (613.4) 71.8 (613.4) 72.5 (613.7) 67 (612.8) 65.4 (614.2) 69.03 (614.7) 68 (613.7)
Charlson scoreb 1 (0–3) 2 (0–3) 2 (1–3) 1 (0–3) 1 (0–2) 1 (0–3) 1 (0–2) 1 (0–2) 1 (0–2) 1 (1–2) 1 (0–1) 1 (0–2)
Memory symptoms,c n
(%)
11 (7) 1 (6) 9 (11) 20 (8) 18 (16) 5 (33) 13 (18) 31 (17) 25 (52) 13 (68) 23 (58) 48 (55)
Hallucinations,c n (%) 0 (0) 0 (0) 0 (0) 0 (0) 2 (12) 0 (0) 3 (4) 5 (3) 4 (8) 3 (16) 6 (15) 10 (11)
Low mood,c n (%) 8 (5) 6 (33) 4 (5) 20 (8) 20 (18) 4 (27) 18 (25) 38 (20) 12 (25) 6 (32) 10 (25) 22 (25)
Dysphagia,c n (%) 2 (1) 0 (0) 4 (5) 6 (3) 23 (20) 5 (33) 12 (16) 35 (19) 11 (23) 4 (21) 8 (20) 19 (22)
Dependency, n (%) 5 (3) 3 (17) 8 (10) 20 (8) 19 (17) 4 (27) 18 (25) 37 (20) 26 (54) 13 (68) 21 (53) 47 (53)
Dementia, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7) 1 (1) 1 (1) 23 (48) 12 (63) 19 (48) 42 (48)
MMSE scoreb 29 (28–30) 29 (28–30) 29 (28–30) 29 (28–30) 29 (27–30) 28 (27–29) 28 (27–29) 29 (27–30) 25 (20–27) 23 (19–27) 25 (21–28.5) 25 (20–28)
UPDRS part I scoreb 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–2) 1 (0–2) 2 (1–3) 2 (1–3) 1 (0–2) 2 (1–3) 3 (1–5) 2 (1–5) 2 (1–3)
UPDRS part II scoreb 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 9.5 (6–14) 10 (6–16) 10.5 (6–14.5) 10 (6–14) 12.5 (7–19.5) 13 (7–17) 10 (7–17) 11 (7–18)
UPDRS part III scoreb 2 (0–4) 2 (1–5) 3 (1–6) 2 (0–5) 23.5 (16–32) 30 (14–34) 26 (18–32) 24 (16–32) 30 (23.5–41) 31 (19–39) 25.5 (178–34.5) 29 (21–39)
Hoehn-Yahr stageb — — — — 2.5 (1.5–2.5) 2.5 (1.5–2.5) 2.5 (2–3) 2.5 (2–3) 3 (2.5–3) 3 (2.5–4) 2.5 (2.25–4) 2.75 (2.5–3.8)
PDQ-8b — — — — 15.6 (6.3–25) 10.9 (6.3–25) 12.5 (6.3–28.1) 15.6 (6.3–25) 15.6 (6.3–31.3) 28.1 (14.0–34.4) 21.9 (9.4–31.3) 17.2 (9.4–31.3)
Barthel Indexb 20 (20–20) 20 (18.5–20) 20 (19–20) 20 (20–20) 20 (19–20) 20 (20–20) 20 (18–20) 20 (19–20) 18.5 (13–20) 17.5 (12.5–19) 19 (16.5–20) 19 (14–20)
Abbreviations: APS 5 atypical parkinsonian syndromes; IPD 5 idiopathic Parkinson disease; MMSE 5 Mini-Mental State Examination; PD 5 Parkinson disease; PDQ-8 5 Parkinson’s Disease Questionnaire-8;
UPDRS 5 Unified Parkinson’s Disease Rating Scale; WL 5 weight loss.
aMean (6SD).
bMedian (IQR).
c Self-reported.
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in patients with atypical parkinsonism (22%) than in
those with PD (8%) and controls (8%) (p 5 0.002,
table 1).
Determinants of weight loss in parkinsonism. The mul-
tivariable Cox regression model examining the deter-
minants of weight loss was constructed for all 275
parkinsonian patients. Variables included and
excluded from the models of outcomes of weight loss
are listed in table 2. At diagnosis, parkinsonian pa-
tients (PD and atypical) who went on to develop
sustained weight loss at any time after diagnosis were
on average 4.5 years older and had a 1-point-higher
median part I Unified Parkinson’s Disease Rating
Scale score than those without sustained weight loss
(table 1).
After multivariable adjustment, only age was
independently associated with developing sustained
clinically significant weight loss at any time after
parkinsonism diagnosis (hazard ratio [HR] 1.83,
95% confidence interval [CI] 1.44–2.32 for each
10-year increase in age) (table 2). There was an indi-
cation that atypical parkinsonism may be associated
with greater weight loss than PD (HR 1.44, 95% CI
0.95–2.18). The association between lower depen-
dency measured by the Barthel Index and weight
loss after adjustment for age and diagnostic group
(table 2) was probably spurious because of
collinearity.
Prognosis of clinically significant weight loss in
parkinsonism. In our parkinsonian cohort (n 5 275),
85 were dependent at baseline, 43 developed depen-
dency by year 1, 97 developed dependency during
later follow-up, and 50 remained independent; 43
had dementia at baseline, 11 developed dementia by
year 1, 57 developed dementia during follow-up, and
164 did not develop dementia. There were 162
deaths. The variables included and excluded from the
models of outcomes of weight loss are listed in table 2.
Sustained clinically significant weight loss within
the first year of diagnosis was independently strongly
associated with subsequent dementia (HR 3.23, 95%
CI 1.40–7.44) and mortality (HR 2.23, 95% CI
1.46–3.41) and was associated with dependency
(HR 2.11, 95% CI 1.00–4.42, p 5 0.05) (table 2).
There was no evidence that the effect of sustained
clinically significant weight loss on these outcomes
was modified by parkinsonian diagnoses (p 5 0.13,
0.93, and 0.20 for interaction in dependency, demen-
tia, and mortality models, respectively). None of the
associations changed if vascular parkinsonism was
excluded.
DISCUSSION This study shows that people with
parkinsonism had significantly lower body weight
than controls at diagnosis. Weight loss was observed
in all groups over time, but patients with PD lost
weight more rapidly than controls, and those with
atypical parkinsonism lost weight most rapidly. Age
was the only independent baseline risk factor for sus-
tained clinically significant weight loss in parkinson-
ism. Clinically significant weight loss within the
first year of diagnosis was independently associated
with subsequent dependency, dementia, and death
after adjustment for potential confounders.
Lower body weight in patients with PD compared
to nonparkinsonian controls has previously been re-
ported.3,19–21 Two independent studies have observed
weight loss occurring up to 10 years before parkin-
sonism diagnosis.2,22 These findings and ours suggest
that weight loss is a feature of premotor and early
motor parkinsonism, probably due to pathologic
mechanisms predating motor symptom onset.
Like most previous studies,1,2,20 we found weight
loss in PD to be greater than in controls. In a small
10-year longitudinal study, the proportion of clini-
cally significant weight loss in patients with PD (n 5
49) was double that among controls.1 Another study
found that patients with PD had 4-fold higher odds
of self-reported weight loss over 8 years.20 The
observed weight loss over time in the PINE study is
consistent with reports that weight loss in parkinson-
ism is associated with disease duration.20 However,
weight measurements in later years of follow-up
may be skewed by attrition due to mortality because
Figure 2 Weight change over time in controls and those with PD and atypical
parkinsonian syndromes
Adjusted yearly estimates of mean weight in kilograms from baseline (from patients’ diag-
nosis and from control recruitment) in controls, patients with idiopathic PD, and those with
atypical parkinsonian syndromes. Bars represent the 95% confidence intervals for each
data point. PD 5 Parkinson disease.
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those who survived longer were less likely to have
early weight loss.
The finding that weight loss was greater in atypical
parkinsonism than in PD is novel. This is in keeping
with the fact that these are more aggressive diseases
than PD and with previous studies in PD that show
that weight loss is associated with greater severity of
parkinsonism.1,20 This study complements data in
other neurodegenerative disorders such as Alzheimer
dementia and Huntington chorea, which are also
associated with weight loss in early and later dis-
ease.23,24 This suggests that there may be mechanisms
common to neurodegenerative disorders, possibly
relating to increased catabolic cellular activity.
Similar to others, we found that age was indepen-
dently associated with sustained clinically significant
weight loss in parkinsonism.1,3,5,10 Unlike this study,
others have found that weight loss was associated with
female sex,3,4,10,25 disease severity,1,10,20 hallucina-
tions,1 levodopa dose,5,25 dyskinesia,19 olfactory
impairment,26 and comorbidities.5 The reason for this
discrepancy may be in part that we studied only base-
line predictors of weight loss and several of these
features are only infrequently present at diagnosis.
Further work to account for changing covariates over
time (e.g., as time-dependent variables in Cox regres-
sion) may be useful. However, later measurement of
predictive factors is less useful for early prediction of
weight loss when targeted interventions could poten-
tially be delivered.
We found that clinically significant weight loss
within the first year of parkinsonism diagnosis was
independently associated with dependency, demen-
tia, and death. This effect was independent of diagno-
sis (PD or atypical), and there was no evidence of an
interaction between weight loss and diagnosis. This
suggests that the greater weight loss seen in atypical
parkinsonism can be explained by the confounders
that we adjusted for in the models. However, we still
may not have detected a small difference because of
a lack of power.
To the best of our knowledge, an association
between weight loss and dependency has not previ-
ously been demonstrated. Our finding complements
previous reports that weight loss and poor nutritional
status in parkinsonism are associated with decreased
Table 2 Multivariable Cox regression models for time to weight loss and time to selected outcomes in parkinsonian patients
Baseline variable
Determinants Time to outcomes
Time to >5% WL (n 5 275) Dependency (n 5 139) Dementia (n 5 220) Death (n 5 258)
HR 95% CI p Value HR 95% CI p Value HR 95% CI p-value HR 95% CI p Value
Sustained clinically
significant weight loss in
year 1
2.11a 1.00–4.42a 0.05a 3.23a 1.40–7.44a 0.006a 2.23a 1.46–3.41a ,0.001a
Atypical parkinsonism (vs
PD)
1.44a 0.95–2.18a 0.09a 2.30a 1.30–4.08a 0.004a 1.05 0.47–2.32 0.91 2.43a 1.70–3.49a ,0.001a
Age (10-y increase) 1.83a 1.44–2.32a ,0.001a 1.42 1.09–1.86 0.01 1.64a 1.12–2.41a 0.01a 1.87a 1.49–2.34a ,0.001a
Male sex 0.96 0.66–1.41 0.87 1.29 0.84–2.00 0.36 1.01 0.56–1.81 0.52 1.40a 1.00–1.96a 0.05a
Charlson score 1.06 0.93–1.20 0.41 1.07 0.93–1.24 0.34 1.03 0.86–1.23 0.86 1.10a 0.99–1.22a 0.07a
Memory symptoms 1.07 0.70–1.66 0.75 2.09a 1.25–3.50a 0.005a 2.58 1.36–4.91 0.004 1.16 0.81–1.67 0.42
Hallucinations 1.58 0.79–3.19 0.20 2.59 0.81–8.31 0.11 0.23 0.03–2.34 0.25 0.83 0.46–1.51 0.55
Low mood 1.43 0.91–2.26 0.13 1.08 0.61–1.92 0.79 1.09 0.57–2.08 0.80 1.27 0.85–1.89 0.25
Dysphagia 0.98 0.60–1.60 0.94 1.36 0.76–2.43 0.30 0.42 0.19–0.95 0.04 1.06 0.72–1.57 0.76
Dependency 1.13 0.73–1.76 0.57 1.45 0.67–3.12 0.34 2.00a 1.39–2.88a ,0.001a
Dementia 1.33 0.72–2.47 0.36 3.06 0.97–9.67 0.06 1.44 0.91–2.27 0.12
MMSE 1.02 0.96–1.09 0.44 0.93 0.82–1.05 0.26 0.90a 0.83–0.97a 0.005a 0.99 0.94–1.03 0.59
UPDRS part I 1.02 0.93–1.12 0.63 1.20 1.01–1.42 0.04 1.28a 1.05–1.56a 0.01a 1.05 0.97–1.14 0.22
UPDRS part II 0.99 0.96–1.02 0.56 1.04 0.97–1.10 0.28 0.98 0.93–1.03 0.18 0.99 0.96–1.02 0.48
UPDRS part III 1.00 0.98–1.01 0.62 1.06a 1.04–1.98a ,0.001a 1.02 0.99–1.04 0.20 1.01 0.99–1.03 0.25
Hoehn-Yahr stage 0.93 0.74–1.17 0.55 0.81 0.51–1.28 0.36 0.99 0.63–1.54 0.95 1.12 0.89–1.40 0.34
Barthel Index 1.09 1.00–1.19 0.04 0.79 0.58–1.05 0.11 1.13 1.02–1.27 0.03 1.05 0.98–1.12 0.15
PDQ-8 1.00 0.99–1.02 0.89 0.99 0.97–1.01 0.32 0.98 0.95–1.00 0.07 0.99 0.98–1.01 0.23
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio; MMSE 5 Mini-Mental State Examination; PDQ-8 5 Parkinson’s Disease Questionnaire-8;
UPDRS 5 Unified Parkinson’s disease rating scale; WL 5 weight loss.
aHazard ratios indicate variables in the final step of each model. Other variables are shown with adjustment for the variables in the final model.
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quality of life,5 worsening disease severity,6 and dys-
kinesias,26 which are often accompanied by increased
dependency.
Associations between weight loss and dementia in
elderly populations have been reported but not in
PD.27,28 Two small prospective studies of PD (n 5
28 and 104) found that patients with weight loss and
low body mass index had significantly worse cognitive
function (after 1 and 3 years of follow-up,
respectively).3,7
Two other studies have specifically investigated
the association between weight loss and mortality in
parkinsonism.4,6 One small retrospective audit (n 5
55) found that weight loss was nonsignificantly asso-
ciated with higher odds of mortality.4 Another large
longitudinal study found no association between
change in body mass index and survival, although this
analysis had few deaths (76 of 1,673 patients).6
Although we have demonstrated an association
between early weight loss and subsequent poor out-
comes, our study was observational, so it cannot
prove causation. However, even if weight loss is sim-
ply a marker of greater disease severity and progres-
sion or a manifestation of general frailty or other
important comorbidities that worsen outcomes, it
may nonetheless be useful clinically. To demonstrate
a causal association, it would be necessary to perform
an intervention trial aimed at preventing weight loss
and to demonstrate that it resulted in improved out-
comes. We are not aware of any such trials in parkin-
sonian disorders; indeed, there are currently no
interventions proven to reduce weight loss in parkin-
sonism.29 Nevertheless, given the association of
weight loss with poor outcomes and the low risk of
harm, it is clearly important that the role of high-
calorie (e.g., high fat and carbohydrate) interventions
be investigated in the early stages of these diseases.
This study has several strengths. First, selection
bias is likely to be low because we studied a popula-
tion-based incident cohort in which efforts were
made to identify all incident cases. There may have
been more selection bias in the control group, but
we have previously shown that the control group
was not overly healthy.30 In addition, because of this
design, the results are likely to be generalizable to the
general population of PD, but there were relatively
few young-onset patients because they make up
a small proportion of the total population with PD.
Second, a relatively large sample size (n 5 275), with
patients followed up prospectively from diagnosis
with regular weight measurements and detailed char-
acterization of clinical features, has provided more
detailed data on predictors and outcomes of weight
loss in parkinsonism and with longer follow-up than
in any previous studies. The use of actual weight
measurements from routinely calibrated scales
improves on previous methods using self-reported
weights.20 Third, we corrected for potential con-
founders and have studied important clinically rele-
vant outcomes.
However, this study does have some limitations.
First, some patients had missing weight data. These
patients often had home visits because they were
too frail to attend the clinic and thus may have been
at greater risk of weight loss and poor outcome. This
could have led to underestimation of differences
between patients and controls and underestimation
of the associations between weight loss and poor out-
come. Second, data on other potential confounders,
including intentional weight change, dietetic inter-
ventions, nutritional status, medication, and potential
external stressors, were not available. Finally, sus-
tained weight loss cannot be used prospectively as
a predictor in early disease because, at the time of
making the predictions, it is not known whether
the weight loss will be sustained.
We have shown that parkinsonian patients have
lower body weight and lose more weight over time
than nonparkinsonian controls and that early clini-
cally significant weight loss was independently associ-
ated with poor outcomes but that it is difficult to
predict at baseline who will lose weight. While causal-
ity cannot be implied, close monitoring of weight
seems advisable in parkinsonism because the identifi-
cation of patients with early weight loss may have
prognostic significance and potential for targeted
intervention. Further work to investigate the effect
of patient characteristics that develop over time in
parkinsonism should be performed, including medi-
cation data, cumulative disease characteristics, and co-
morbidities. Targeted interventions to prevent or
reverse weight loss in parkinsonism may improve out-
comes, and there is therefore a strong case to investi-
gate such interventions in randomized trials.
AUTHOR CONTRIBUTIONS
Kirsten Cumming: study concept and design, analysis and interpretation
of data, statistical analysis, first draft of manuscript. Angus D. Macleod:
study concept and design, acquisition of data, analysis and interpretation
of data, statistical analysis, study supervision, critical revision of manu-
script for intellectual content. Phyo K. Myint: study concept and design,
study supervision, critical revision of manuscript for intellectual content.
Carl E. Counsell, study concept and design, acquisition of data, study
supervision, critical revision of manuscript for intellectual content.
ACKNOWLEDGMENT
The authors thank all the participants who took part, research fellows
(Kate Taylor, Robert Caslake, David McGhee) and study nurses (Clare
Harris, Joanna Gordon, Anne Hayman, Hazel Forbes) who undertook
the assessments, secretaries (Susan Kilpatrick, Pam Rebecca), data manage-
ment team (Katie Wilde, David Ritchie), clinicians who referred patients
to the PINE study, and study funders.
STUDY FUNDING
This study was funded by Parkinson’s UK, the Scottish Chief Scientist
Office, NHS Grampian Endowments, the BMA Doris Hillier award, RS
2260 Neurology 89 November 28, 2017
Macdonald Trust, the Bupa Foundation, and the Special Parkinson’s
Research Interest Group.
DISCLOSURE
K. Cumming reports no disclosures relevant to the manuscript.
A. Macleod has received funding support from the Chief Scientist Office
of the Scottish Government, Parkinson’s UK, NHS Grampian Endow-
ments, the Wellcome Trust, the University of Aberdeen, and the Acad-
emy of Medical Sciences. P. Myint has received funding support from the
NIHR (Research for Patient Benefit Programme, HTA Programme, and
Programme Grant for Applied Research), NHS Grampian Endowments,
Sir Halley Stewart Trust, Dunhill Medical Trust, Medical Research Scot-
land, Tenovus Scotland, Stroke Association, Alzheimer’s Society, and
British Geriatrics Society. C. Counsell has received funding support from
Parkinson’s UK, the Chief Scientist Office of the Scottish Government,
the Engineering and Physical Sciences Research Council, and NHS
Grampian Endowments. Go to Neurology.org for full disclosures.
Received May 13, 2017. Accepted in final form September 11, 2017.
REFERENCES
1. Uc EY, Struck LK, Rodnitzky RL, Zimmerman B,
Dobson J, Evans WJ. Predictors of weight loss in Parkin-
son’s disease. Mov Disord 2006;21:930–936.
2. Chen H, Zhang SM, Hernan MA, Willett WC,
Ascherio A. Weight loss in Parkinson’s disease. Ann
Neurol 2003;53:676–679.
3. Lorefält B, Ganowiak W, Pålhagen S, Toss G, Unosson
M, Granérus AK. Factors of importance for weight loss in
elderly patients with Parkinson’s disease. Acta Neurol
Scand 2004;110:180–187.
4. Walker R, Davidson M, Gray W. Gender differences in 1-year
survival rates after weight loss in people with idiopathic
Parkinson’s disease. Int J Palliat Nurs 2012;18:35–39.
5. Akbar U, He Y,Wu S, et al. Weight loss and impact on quality
of life in Parkinson’s disease. PLoS One 2015;10:e0124541.
6. Wills AM, Perez A, Wang J, et al. Association between
change in body mass index, Unified Parkinson’s Disease
Rating Scale scores, and survival among persons with Par-
kinson disease: secondary analysis of longitudinal data
from NINDS Exploratory Trials in Parkinson Disease
Long-Term Study 1. JAMA Neurol 2016;73:321–328.
7. Kim HJ, Oh ES, Lee JH, et al. Relationship between changes
of body mass index (BMI) and cognitive decline in Parkin-
son’s disease (PD). Arch Gerontol Geriatr 2012;55:70–72.
8. Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK.
Improved nutritional status is related to improved quality of
life in Parkinson’s disease. BMC Neurol 2014;14:212–220.
9. Sharma JC, Vassallo M. Prognostic significance of weight
changes in Parkinson’s disease: the Park-weight pheno-
type. Neurodegener Dis Manag 2014;4:309–316.
10. Wills A-M, Ruosha L, Perez A, Ren X, Boyd J. Predictors
of weight loss in early treated Parkinson’s disease from the
NET-PD LS-1 cohort. J Neurol 2017;264:1746–1753.
11. Taylor KS, Counsell CE, Harris CE, Gordon JC, Smith
WC. Pilot study of the incidence and prognosis of degen-
erative Parkinsonian disorders in Aberdeen, United King-
dom: methods and preliminary results. Mov Disord 2006;
21:976–982.
12. Caslake R, Taylor K, Scott N, et al. Age-, gender-, and
socioeconomic status-specific incidence of Parkinson’s dis-
ease and parkinsonism in North East Scotland: the PINE
study. Parkinsonism Relat Disord 2013;19:515–521.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of
clinical diagnosis of idiopathic Parkinson’s disease:
a clinico-pathological study of 100 cases. J Neurol Neuro-
surg Psychiatry 1992;55:181–184.
14. Bouras EP, Lange SM, Scolapio JS. Rational approach to
patient with unintentional weight loss. Mayo Clin Proc
2001;76:923–929.
15. Schwab RS, England AC. Projection technique for evalu-
ating surgery in Parkinson’s disease. In: Gillingham FJ,
Donaldson MC, eds. Third Symposium on Parkinson’s
Disease. Edinburgh: E & S Livingston; 1969:152–157.
16. Caslake R, Summers F, McConachie D, et al. The Mini-
Mental Parkinson’s (MMP) as a cognitive screening tool in
people with Parkinson’s disease. Curr Aging Sci 2013;6:
273–279.
17. Macleod AD, Goddard H, Counsell CE. Co-morbidity
burden in Parkinson’s disease: comparison with controls
and its influence on prognosis. Parkinsonism Relat Disord
2016;28:124–129.
18. Peduzzi P, Concato J, Feinstein AR, Holford TR. Impor-
tance of events per independent variable in proportional
hazards regression analysis, II: accuracy and precision of
regression estimates. J Clin Epidemiol 1995;48:1503–1510.
19. Markus HS, Cox M, Tomkins AM, Stern GM. Increased
prevalence of undernutrition in Parkinson’s disease and its
relationship to clinical disease parameters. J Neural
Transm Park Dis Dement Sect 1993;5:117–125.
20. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller
WC. Weight change and body composition in patients with
Parkinson’s disease. J Am Diet Assoc 1995;95:979–983.
21. Van der Merck MA, Dicke HC, Uc EY, et al. Body mass
index in Parkinson’s disease: a meta-analysis. Parkinsonism
Relat Disord 2012;18:263–267.
22. Logroscino G, Sesso HD, Paggenbarger RS, Lee IM. Body
mass index and risk of Parkinson’s disease: a prospective
cohort study. Am J Epidemiol 2007;166:1186–1190.
23. Besser LM, Gill DP, Monsell SE, et al. Body mass index,
weight change, and clinical progression in mild cognitive
impairment and Alzheimer disease. Alzheimer Dis Assoc
Disord 2014;28:36–43.
24. Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson
I, Myers RH. Weight loss in early stage of Huntington’s
disease. Neurology 2002;59:1325–1330.
25. Sharma JC, Turton J. Olfaction, dyskinesia and profile of
weight change in Parkinson’s disease: identifying neurode-
generative phenotypes. Parkinsonism Relat Disord 2012;
18:964–970.
26. Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I.
Cascade of levodopa dose and weight related dyskinesia in
Parkinson’s disease (LD–WD–PD cascade). Parkinsonism
Relat Disord 2006;12:499–505.
27. Stewart R, Masaki K, Xue QL, et al. A 32-year prospec-
tive study of change in body weight and incident demen-
tia: the Honolulu-Asia Aging Study. Arch Neurol 2005;
62:55–60.
28. Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D,
Fratiglioni L. Late-life body mass index and dementia inci-
dence: nine-year follow-up data from the Kungsholmen
Project. J Am Geriatr Soc 2008;56:111–116.
29. Payne C, Wiffen PJ, Martin S. Interventions for fatigue
and weight loss in adults with advanced progressive illness.
Cochrane Database Syst Rev 2012;1:CD008427.
30. Taylor KSM, Gordon JC, Harris CE, Counsell CE.
Recruitment bias resulted in poorer overall health status
in a community-based control group. J Clin Epidemiol
2008;61:890–895.
Neurology 89 November 28, 2017 2261
